new idea award

New Idea Award Recipients

This year, we introduced a research award to funnel a stream of projects that support innovative approaches that may fundamentally change our understanding, diagnosis and/or treatment of blood cancers. 

The New Idea Award recognizes researchers who are investigating potentially transformative ideas to significantly improve clinical outcomes for patients with blood cancers. These research projects may eventually lead to significant improvements in the clinical outcomes of patients with hematological malignancies.

 

Donate Today      

New Idea Awardees

Dr. Keith Brunt

Dr. Keith Brunt

Dalhousie University
Halifax, Nova Scotia Developing an innovative treatment monitoring tool in multiple myeloma Multiple myeloma does not yet have a cure, but because of research investments it can be controlled.  To control myeloma, we need very sensitive medical tools. These tools detect when the myeloma flares up and needs to be treated. The sooner we know when to treat, the better quality of li...

Dr. DaCosta

Dr. DaCosta

University Health Network
Toronto, Ontario In Vivo Studies of Acute Myeloid Leukemia and its Hypoxia Status within the Bone Marrow Microenvironment     Acute myeloid leukemia (AML) is a disease of the bone marrow (BM) that spreads throughout the BM of affected patients. The BM microenvironment supports the development of leukemic cells, and typically the BM is hypoxic (low oxygen).&nb...

Dr. Kim

Dr. Kim

University Health Network
Toronto, Ontario Impact of clonal hematopoiesis in donors on allogeneic hematopoietic stem cell transplantation outcomes    Allogeneic hematopoietic stem cell transplant still remains the only curative treatment modality in many of hematologic malignancy treatment. It requires transfer of hematopoietic stem cells from healthy donor to the recipient, i.e. patient w...

Dr. Kuruvilla

Dr. Kuruvilla

University Health Network
Toronto, Ontario Manipulating Gamma Delta T-cell metabolism for Improved Cytotoxicity in Hematological Malignancies Harnessing the potential of the immune system to combat blood cancers represents a new approach that has started to change the standard of care. A growing body of evidence indicates that as immune cells switch from an inactive mode to a cancer-killing mode they und...

Dr. Laverdiere

Dr. Laverdiere

Laval University
Québec, Québec Elucidation of the functional role of Complement Factor D in Acute Myeloid Leukemia. Acute myeloid leukemia (AML) is the second most common type of leukemia in both children and adults for which the survival rate remains poor. The proposed research intends to elucidate the function of a novel prognosis marker in AML. In particular, we will characterize its role on cancer...

Dr. Mercier

Dr. Mercier

Jewish General Hospital/LDI
Montréal, Québec Tracking of clonal evolution in acute myeloid leukemia using single-cell RNA sequencing In individuals with cancer, not all cancerous cells are the same: some carry different genetic changes or have different potential to proliferate and spread. Single-cell RNA sequencing means that we can now analyze the genetic signature of thousands of single cells isolat...

Dr. Nelson

Dr. Nelson

BC Cancer Agency
Victoria, British Columbia Mutual Antibody T cell Engagers (MATEs): a safe, flexible alternative to CAR-T cells for the treatment of leukemia and lymphoma    The world has seen a major breakthrough in the treatment of leukemias and lymphomas using “CAR-T cells”, a new strategy in which T cells are genetically engineered to express “Chimeric Antigen Receptors” that ...

Dr. Saini

Dr. Saini

University of Alberta
Edmonton, Alberta                   Assessment of minimal residual disease in patients undergoing treatment for acute myeloid leukemia using an in vivo xenotransplantation model Acute Myeloid Leukemia (AML) is an aggressive blood cancer. About 80% of people can achieve a remission with our stan...

Dr. Wilhelm

Dr. Wilhelm

University of Montréal
Montréal, Québec                      Microfluidic detection of leukemia cells by electronic biomolecular sensors      Acute myeloid leukemia (AML) is a disease caused by the uncontrolled growth of primitive myeloid progenitor cells. Patients with AML...

Dr. Wurtele

Dr. Wurtele

Hôpital Maisonneuve-Rosemont
Montréal, Québec Oncometabolite-induced DNA replication defects in leukemia  Unlike normal blood cells which divide only when necessary, leukemic cells divide uncontrollably and in doing so are constantly duplicating their genetic material (i.e., their DNA) in a process called “DNA replication”. Chemotherapy drugs cause lethal damage specifically to replicating DN...